This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZIOP ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ZIOPHARM Oncology Stock (NASDAQ:ZIOP) 30 days 90 days 365 days Advanced Chart Get ZIOPHARM Oncology alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.82▼$1.3952-Week Range N/AVolume2.13 million shsAverage Volume2.01 million shsMarket Capitalization$187.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA. Read More Receive ZIOP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address ZIOP Stock News HeadlinesTCRT stock touches 52-week low at $1.62 amid market challengesJanuary 30, 2025 | msn.comBest Global Universities for OncologySeptember 11, 2024 | usnews.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 11 at 2:00 AM | Porter & Company (Ad)Alx Oncology Holdings (ALXO)February 10, 2024 | investing.comCG Oncology IncJanuary 31, 2024 | reuters.comWhy Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?December 18, 2023 | markets.businessinsider.comWBSPH 2024 - OncologySeptember 15, 2023 | newsweek.comNGauging Ziopharm's Chances for Positive Sarcoma Drug Trial ResultsAugust 29, 2023 | thestreet.comSee More Headlines ZIOP Stock Analysis - Frequently Asked Questions How were ZIOPHARM Oncology's earnings last quarter? ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) released its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $0.40 million during the quarter. What other stocks do shareholders of ZIOPHARM Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ZIOPHARM Oncology investors own include Precigen (PGEN), Bristol Myers Squibb (BMY), OPKO Health (OPK), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN) and CorMedix (CRMD). Company Calendar Last Earnings11/08/2021Today7/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ZIOP CIK1107421 Webwww.ziopharm.com Phone(617) 259-1970Fax617-241-2855Employees105Year Founded2005Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.98 million Net MarginsN/A Pretax Margin-22,544.97% Return on Equity-92.84% Return on Assets-72.46% Debt Debt-to-Equity Ratio0.18 Current Ratio3.43 Quick Ratio3.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / BookN/AMiscellaneous Outstanding Shares216,146,000Free Float204,906,000Market Cap$187.12 million OptionableOptionable Beta1.71 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ZIOP) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIOPHARM Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIOPHARM Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
